MX2023014784A - Preparacion de derivados de compuestos 1,2-diaminoheterociclicos sustituidos y su uso como agentes farmaceuticos. - Google Patents
Preparacion de derivados de compuestos 1,2-diaminoheterociclicos sustituidos y su uso como agentes farmaceuticos.Info
- Publication number
- MX2023014784A MX2023014784A MX2023014784A MX2023014784A MX2023014784A MX 2023014784 A MX2023014784 A MX 2023014784A MX 2023014784 A MX2023014784 A MX 2023014784A MX 2023014784 A MX2023014784 A MX 2023014784A MX 2023014784 A MX2023014784 A MX 2023014784A
- Authority
- MX
- Mexico
- Prior art keywords
- diaminoheterocyclic
- substituted
- preparation
- pharmaceutical agents
- compound derivatives
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 abstract 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2108249.0A GB202108249D0 (en) | 2021-06-09 | 2021-06-09 | Compounds |
| PCT/KR2022/008105 WO2022260441A1 (en) | 2021-06-09 | 2022-06-09 | Preparation of substituted 1,2-diaminoheterocyclic compound derivatives and their use as pharmaceutical agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014784A true MX2023014784A (es) | 2024-03-25 |
Family
ID=76838874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014784A MX2023014784A (es) | 2021-06-09 | 2022-06-09 | Preparacion de derivados de compuestos 1,2-diaminoheterociclicos sustituidos y su uso como agentes farmaceuticos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240300936A1 (https=) |
| EP (1) | EP4352049A4 (https=) |
| JP (1) | JP2024522201A (https=) |
| KR (1) | KR20240006692A (https=) |
| CN (1) | CN117529476A (https=) |
| AU (1) | AU2022291332A1 (https=) |
| CA (1) | CA3216629A1 (https=) |
| GB (1) | GB202108249D0 (https=) |
| MX (1) | MX2023014784A (https=) |
| WO (1) | WO2022260441A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250096877A (ko) * | 2022-12-12 | 2025-06-27 | 아벨로스테라퓨틱스 주식회사 | 치환된 헤테로고리 화합물 유도체 및 그의 약학적 용도 |
| WO2024137979A2 (en) * | 2022-12-23 | 2024-06-27 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Foxm1 inhibitors and their use in treating cancers |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| JP5743897B2 (ja) * | 2008-11-20 | 2015-07-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 化合物 |
| JP5856151B2 (ja) * | 2010-05-12 | 2016-02-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼ阻害剤として有用な２−アミノピリジン誘導体 |
| US9481670B2 (en) * | 2011-01-25 | 2016-11-01 | Sphaera Pharma Pte. Ltd. | Triazine compounds |
| US9604937B2 (en) * | 2012-11-27 | 2017-03-28 | Thomas Helledays Stiftelse For Medicinsk Forskning | Pyrimidine-2,4-diamine derivatives for treatment of cancer |
| CN106794181A (zh) * | 2014-06-04 | 2017-05-31 | 托马斯·黑勒戴药物研究基金会 | 用于治疗炎性和自身免疫性病况的mth1抑制剂 |
-
2021
- 2021-06-09 GB GBGB2108249.0A patent/GB202108249D0/en not_active Ceased
-
2022
- 2022-06-09 CN CN202280041809.1A patent/CN117529476A/zh active Pending
- 2022-06-09 JP JP2023576071A patent/JP2024522201A/ja active Pending
- 2022-06-09 WO PCT/KR2022/008105 patent/WO2022260441A1/en not_active Ceased
- 2022-06-09 MX MX2023014784A patent/MX2023014784A/es unknown
- 2022-06-09 EP EP22820568.8A patent/EP4352049A4/en active Pending
- 2022-06-09 KR KR1020237043163A patent/KR20240006692A/ko active Pending
- 2022-06-09 US US18/568,365 patent/US20240300936A1/en active Pending
- 2022-06-09 CA CA3216629A patent/CA3216629A1/en active Pending
- 2022-06-09 AU AU2022291332A patent/AU2022291332A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4352049A4 (en) | 2025-05-21 |
| EP4352049A1 (en) | 2024-04-17 |
| CN117529476A (zh) | 2024-02-06 |
| WO2022260441A1 (en) | 2022-12-15 |
| KR20240006692A (ko) | 2024-01-15 |
| JP2024522201A (ja) | 2024-06-11 |
| GB202108249D0 (en) | 2021-07-21 |
| CA3216629A1 (en) | 2022-12-15 |
| US20240300936A1 (en) | 2024-09-12 |
| AU2022291332A1 (en) | 2023-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| PH12020551305A1 (en) | Pharmaceutical Compounds | |
| JOP20230113A1 (ar) | مشتقات ثلاثية الكربوكساميد كمثبطات prmt5 | |
| PH12019502245A1 (en) | Compounds that inhibit mcl-1 protein | |
| PH12019500214A1 (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| PH12021552482A1 (en) | Compounds targeting prmt5 | |
| MX2022005775A (es) | Compuestos terapeuticos y metodos de uso. | |
| EP3693369A3 (en) | Bromodomain inhibitors | |
| MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| WO2025049274A3 (en) | Tetracyclic derivatives, compositions and methods thereof | |
| AU2020231934A8 (en) | Compounds useful in HIV therapy | |
| MX2023002907A (es) | Compuestos heterociclicos como inhibidores del bromodominio cbp/ep300. | |
| PH12022551623A1 (en) | Substituted pyrazolo-pyrimidines and uses thereof | |
| MX2021006520A (es) | Compuestos heteroaromaticos como inhibidores de vanina. | |
| MX2021002323A (es) | Compuestos heteroaromaticos como inhibidores de vanina. | |
| WO2020190890A8 (en) | Nicorandil derivatives | |
| MX2023014589A (es) | Compuestos anticancer. | |
| MX2023004008A (es) | Derivados de tetrazol como inhibidores de trpa1. | |
| MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
| MX2023011829A (es) | Derivados de uracilo como inhibidores de trpa1. | |
| MX2024002409A (es) | Terapias contra el cancer. | |
| MX2023005913A (es) | Derivados de bencenosulfonamida y usos de los mismos. | |
| MX2023003516A (es) | Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7). |